Skip to content

Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)

Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06247150
Acronym
TIL-GVHD
Enrollment
70
Registered
2024-02-07
Start date
2024-05-21
Completion date
2028-06-01
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Graft Versus Host Disease

Keywords

Chronic GVHD, Biopsy, TFH, Tertiary lymphoid structures

Brief summary

Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD). The latter occurs in nearly 50% of patients and its pathogenesis remains poorly understood. Previous translational studies have delineated biological immune dysregulation involved in cGVHD and facilitated the development of new drug and therapeutic strategies. New aspects of T and B cells collaboration in the context of cGVHD using blood description of a key player called TFH, classicaly involved in germinal center reaction, were previously uncovered (Forcade et al, Blood 2016). Previous studies in the context of auto-immune inflammation (lupus nephritis) or organ transplant rejection, suggested that target tissue could contain accessory lymphoid structures (TLS). The description of such structures in cGVHD target tissue would give the opportunity to directly analyze immune key player involved the pathogenesis of cGVHD.

Detailed description

Context : Chronic Graft versus Host Disease (cGVHD) represents the main cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (alloSCT), occurring in 30 and 60%. Translational studies showed that different alloreactive T cell subsets were involved and associated with cGVHD, and regulatory subsets were deficient. Several homeostatic abnormalities of B cell subsets were also shown, which, in the context of high BAFF level, contributed to autoreactive B cell clone emergence. In alloSCT patients, we observed (Forcade et al, Blood 2016) in the blood, a T cell subset called TFH, with B cell help capacity, similar to germinal center reaction. During cGVHD, blood TFH were highly activated, skewed toward a Th1/Th17 profile, and presented enhanced capacity to provide " help " to B cells, promoting auto-/allo-antibody production in the context of cGVHD. This was associated with increased level of CXCL13 in such patients, suggesting homing of this subset to lymphoid tissues. Liarski et al (Sci Trans Med 2014) showed that TFH were observed in inflamed tissue sample from patients with lupus, and demonstrated close interaction with B cells, mimicking germinal center structures, such as tertiary lymphoid organs. Preliminary data, on cGVHD tissue target, showed a CD4+ T cell infiltrate, of which some expressed CXCR5, ICOS, PD1 in single staining. Hypothesis : cGVHD target tissue contains tertiary lymphoid structures.

Interventions

The procedure will consist of an additional blood sample for 3 ETDA tubes collection (NGS analysis) and citrate tube collection (NETose analysis)

BIOLOGICALcGVHD target tissue biopsy

For chronic GVH patients only, cGVHD target tissue biopsy

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient \> 18 yo ; * Having undergone an allogeneic stem cell tranplant ; * 2 groups of patients will be eligible * showing evidence of primary cGVHD or occuring after Donor Lymphocyte Infusion * in the case of first occurrence of cGVHD, in the absence of any new systemic therapy ; * in the case of recurrent cGVHD, steroid dose has to be below 15mg/day of Prednisone ; * Having read, understood and signed an informed consent of the study; * With social security affiliation;

Exclusion criteria

* Patient below 18 yo or unable to give consent ; * Systemic therapy using steroids over 15mg/d of Prednisone ; and/or the use of other systemic agent introduced in the last month ; * Haemorrhagic risk of biopsy anticipated ; * Absence of patient agreement for the study

Design outcomes

Primary

MeasureTime frameDescription
To describe immune landscape in chronic GVHDtarget tissuesubsets, especially TFH, within cGVHD tissue target, using flow cytometry and histologyAt inclusion visitFlow cytometry and multiplex tissue imaging. GVHD evaluation using NIH score

Countries

France

Contacts

CONTACTEdouard FORCADE
edouard.forcade@chu-bordeaux.fr+33557656511

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026